Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep 24;571(1):33-8.
doi: 10.1016/j.ejphar.2007.06.003. Epub 2007 Jun 13.

Lobelane decreases methamphetamine self-administration in rats

Affiliations

Lobelane decreases methamphetamine self-administration in rats

Nichole M Neugebauer et al. Eur J Pharmacol. .

Abstract

Lobelane, a minor alkaloid of Lobelia inflata and a synthetic, des-oxy analog of lobeline, has good affinity for the vesicular monoamine transporter and the dopamine transporter. The current study examined the ability of lobelane to specifically decrease methamphetamine self-administration. Rats were trained on a fixed ratio 5 schedule of reinforcement to self-administer methamphetamine (0.05 mg/kg/infusion, i.v.) or to respond for sucrose pellets. Upon reaching stable responding, rats were pretreated with lobelane (0.1, 1, 3, 5.6, or 10 mg/kg, s.c.) or saline, 15 min prior to the operant session. To assess the effect of repeated lobelane on methamphetamine self-administration, rats were pretreated with lobelane (5.6 or 10 mg/kg, s.c.) for 7 sessions. Behavioral specificity was further investigated by assessing the effects of lobelane (0.1, 1, 3, 5, or 10 mg/kg, s.c.) or saline on locomotor activity. Within the dose range tested, lobelane dose-dependently decreased methamphetamine self-administration, while having no effect on sucrose-maintained responding. Locomotor activity was decreased following only the highest dose of lobelane (10 mg/kg). Across repeated pretreatments, tolerance developed to the effect of lobelane on methamphetamine self-administration, demonstrating that the ability of lobelane to specifically decrease methamphetamine self-administration is a transient effect. Thus, taken together, the results show that although lobelane interacts with the pharmacological targets believed to be responsible for its ability to decrease methamphetamine self-administration, removal of the oxygen functionalities from the lobeline molecule may have afforded a compound with an altered pharmacokinetic and/or pharmacodynamic profile.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Chemical Structures of Lobeline and Lobelane
Figure 2
Figure 2. Dose and Time Course Effects of Acute Lobelane Pretreatment on Methamphetamine Self-Administration
Data represent the mean number of infusions (± S.E.M.) obtained during each 5-min interval of the methamphetamine self-administration session following lobelane (5.6 or 10 mg/kg) or saline. * indicates a significant difference of both doses from saline control at the time point indicated (P < 0.05)
Figure 3
Figure 3. Dose Effect of Acute Lobelane on Methamphetamine Self-Administration and Sucrose-Maintained Responding
Data represent the mean number of sucrose pellets or methamphetamine infusions (± S.E.M.) earned during the first 15 min of the 60-min operant session following pretreatment with lobelane (0.1–10 mg/kg) or saline. *indicates a significant difference from saline control (P < 0.05)
Figure 4
Figure 4. Dose Effect of Acute Lobelane on Locomotor Activity
Data represent the mean total distance traveled (± S.E.M.) during the 15–30 min time interval, which corresponded to the first 15 min of the operant session in the operant conditioning experiments. *indicates a significant difference from saline control (P < 0.05, one-tailed).
Figure 5
Figure 5. Dose Effect of Repeated Lobelane (5.6 or 10 mg/kg) on Methamphetamine Self-Administration
Data represent the mean number of methamphetamine infusions (± S.E.M.) earned during the first 15 min of the session following repeated administration of lobelane (5.6 or 10 mg/kg) across 7 sessions. *indicates a significant difference from baseline infusions (P < 0.05).

Similar articles

Cited by

References

    1. Abood LG, Banerjee S, Kanne DB. Sites, mechanisms, and structural characteristics of the brain's nicotine receptor. J. Subst. Abuse. 1989;1:259–271. - PubMed
    1. Baumann MH, Phillips JM, Ayestas MA, Ali SF, Rice KC, Rothman RB. Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence. Ann. N.Y. Acad. Sci. 2002;965:92–108. - PubMed
    1. Benwell ME, Balfour DJ. The influence of lobeline on nucleus accumbens dopamine and locomotor responses to nicotine in nicotine-pretreated rats. Br. J. Pharmacol. 1998;125:1115–1119. - PMC - PubMed
    1. Damaj MI, Patrick GS, Creasy KR, Martin BR. Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther. 1997;282:410–419. - PubMed
    1. Dwoskin LP, Crooks PA. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 2002;63:89–98. - PubMed

Publication types

MeSH terms